Amir R Jalilian1, Akbar Anvari2, Ali Bahrami-Samani1, Mohammad Mazidi1, Mohammad Ghannadi-Maragheh1. 1. Radiopharmaceutical Research and Development Laboratory (RRDL), Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran 14155-1339. 2. Faculty of Nuclear Engineering, Shahid Beheshti University, P.O. Box: 19839-63113, Tehran, Iran.
Abstract
BACKGROUND: (66)Ho-chloride was obtained by bombardment of natural Ho(NO3)3 dissolved in acidic media using thermal neutron flux (4-5 × 10(13) n.cm(-2).s(-1)). METHODS: (166)Ho-holmium chloride (185 MBq) was used successfully for preparation of (166)Ho-phytate complex with high radiochemical purity (>99.9 %, ITLC, MeOH: H2O: acetic acid, 4: 4: 2, as mobile phase). The complex stability and viscosity were checked in the final solution up to 2 days. The prepared complex solution (60 μCi/100 μl) was injected intraarticularly to male rat knee joints. Leakage of radioactivity from the injection site and its distribution in organs were investigated up to 2 days. RESULTS: Approximately all of the injected dose had remained in the injection site 2 days after injection. CONCLUSION: The complex was proved to be a feasible agent for cavital radiotherapy in oncology and rheumatology.
BACKGROUND: (66)Ho-chloride was obtained by bombardment of natural Ho(NO3)3 dissolved in acidic media using thermal neutron flux (4-5 × 10(13) n.cm(-2).s(-1)). METHODS: (166)Ho-holmium chloride (185 MBq) was used successfully for preparation of (166)Ho-phytate complex with high radiochemical purity (>99.9 %, ITLC, MeOH: H2O: acetic acid, 4: 4: 2, as mobile phase). The complex stability and viscosity were checked in the final solution up to 2 days. The prepared complex solution (60 μCi/100 μl) was injected intraarticularly to male rat knee joints. Leakage of radioactivity from the injection site and its distribution in organs were investigated up to 2 days. RESULTS: Approximately all of the injected dose had remained in the injection site 2 days after injection. CONCLUSION: The complex was proved to be a feasible agent for cavital radiotherapy in oncology and rheumatology.
Authors: Hazel Breitz; Richard Wendt; Michael Stabin; Lionel Bouchet; Barry Wessels Journal: Cancer Biother Radiopharm Date: 2003-04 Impact factor: 3.099